MUC1 is a transmembrane mucin that was initially cloned from malignant mammary epithelial cells as a tumor antigen. More than 90% of human breast carcinomas overexpress MUC1. Numerous studies have demonstrated an interaction between MUC1 and other oncogenic proteins such as b-catenin, erbB receptors and c-Src, but a functional role for MUC1 in transformation has not been identified. We previously reported the development of transgenic mice that overexpress human MUC1 in the mouse mammary gland (MMTV-MUC1). Analysis of these transgenic mice at an early age demonstrated the ability of MUC1 to potentiate EGF-dependent activation of MAP kinase signaling pathways in the lactating mammary gland. We now report that multiparous MMTV-MUC1 transgenic mice stochastically develop unifocal mammary gland carcinomas late in life. Molecular analysis of these tumors shows a tumor-specific coimmunoprecipitation between MUC1 and b-catenin. Examination of the contralateral glands in MMTV-MUC1 transgenics demonstrates that the development of frank carcinomas is accompanied by a failure of multiparous glands to undergo postlactational involution. Furthermore, uniparous MMTV-MUC1 transgenic mice display decreased postlactational apoptosis, elevated whey acidic protein expression and aberrant pErk2 activation. These findings are the first to determine that MUC1 overexpression promotes in vivo transformation of the mammary gland.
Introduction
MUC1 is a transmembrane mucin that was initially cloned from malignant mammary epithelial cells as a tumor antigen (Gendler et al., 1987) . MUC1 contains both a heavily glycosylated extracellular domain and a highly conserved cytoplasmic domain (Gendler et al., 1990; Lan et al., 1990; Ligtenberg et al., 1990; Wreschner et al., 1990) . While it is normally expressed on the apical surfaces of most glandular epithelia, MUC1 is expressed over the entire surface of transformed epithelial cells, displaying an altered pattern of glycosylation.
While MUC1 has been identified as aberrantly expressed in greater than 90% of human breast carcinomas (Zotter et al., 1988; Girling et al., 1989) , the identification of a functional role for that overexpression has been elusive. Transgenic and knockout mice have provided insight into the role of MUC1 in tumor development, with the loss of Muc1 resulting in a reduction in tumor progression. Transgenic mice expressing the polyomavirus middle T antigen (PyV MT) under control of the mouse mammary tumor virus (MMTV) promoter exhibit a significant delay in tumor growth and a trend towards decreased metastasis when bred onto a Muc1 knockout background (Spicer et al., 1995b) . Also, lack of Muc1 expression causes a significant delay in tumor onset in the MMTV-Wnt-1 model of breast cancer (Schroeder et al., 2003) . Mammary tumors of MMTV-PyV MT and MMTVWnt-1 transgenic mice overexpress Muc1, and as such recapitulate the overexpression of human MUC1 observed in most breast carcinomas. Together, these studies indicate that MUC1 is not merely overexpressed in breast cancer but also plays an important role in the progression towards invasive carcinoma.
Numerous observations point to a functional role of MUC1 in signal transduction. The 72 amino-acid tail of MUC1 contains seven tyrosines, six of which are 100% conserved across mammalian species. The cytoplasmic tail of MUC1 contains potential docking sites for SH2-containing proteins in addition to a number of possible kinase recognition sites (Spicer et al., 1995a) . Indeed, MUC1 cytoplasmic tail interacts with a variety of proteins involved in neoplasia and cell adhesion such as epidermal growth factor receptor (EGFR), erbB2, erbB3, erbB4, c-Src, protein kinase C delta (PKCd), Grb2, b-catenin, GSK3b and p120 ctn (Pandey et al., 1995; Yamamoto et al., 1997; Li and Kufe, 2001; Li et al., 2001a, b; Schroeder et al., 2001 Schroeder et al., , 2003 Ren et al., 2002) . In vitro studies show that a defined sequence in the cytoplasmic tail of MUC1 (SXXXXXSSLS) interacts with b-catenin, and can compete with E-cadherin at adherens junctions for binding of b-catenin when expressed at high levels (Yamamoto et al., 1997) . The serine/threonine kinase GSK3b can also bind the cytoplasmic domain of MUC1, and binding to this kinase competes away binding between MUC1 and bcatenin in breast cancer cell lines (Li et al., 1998) . Studies in our lab determined that MUC1 and b-catenin biochemically interact in a tumor-specific manner in MMTV-Wnt-1 transgenic mice (Schroeder et al., 2003) . Finally, both c-Src and the erbB receptor tyrosine kinases phosphorylate MUC1, as well as the serine/ threonine kinase PKCd, and these phosphorylation events promote interactions between b-catenin and MUC1 (Li et al., 2001a, b; Schroeder et al., 2001; Ren et al., 2002) . These observations indicate that the cytoplasmic domain of MUC1 may provide a protooncogenic signal.
We have previously reported the generation of transgenic mouse models overexpressing various forms of MUC1 in the mouse mammary gland (Schroeder et al., 2001) . Using the MMTV promoter, we directed the expression of either full-length, cytoplasmic domaindeleted or tandem repeat-deleted human MUC1 to the mammary gland in an effort to understand the effects of MUC1 overexpression in this tissue. These studies allowed us to determine a variety of signaling partners and downstream effects of MUC1 overexpression (including interacting with erbB receptors and potentiation of Erk1 and Erk2 activation). An expansion of our analysis of the MMTV-MUC1 transgenics included a long-term study of MUC1 overexpression, which resulted in the observation that MUC1 overexpression results in frank neoplasia accompanied by a failure of multiparous glands to dedifferentiate and involute. We have determined that this lack of involution can be observed in nontumor-bearing mammary glands as well, in that postlactational regression is suppressed by MUC1 overexpression. These data show, for the first time, that MUC1 can act as a promoter of transformation in the mammary gland. Furthermore, these data indicate that the mechanism for MUC1-induced tumorigenesis may be through the inhibition of normal glandular involution.
Results

MUC1 overexpression results in the stochastic formation of mammary gland tumors
We previously described the analysis of three MUC1 transgenic mouse models, one overexpressing full-length human MUC1 (MMTV-MUC1), a second overexpressing human MUC1 lacking the cytoplasmic domain (MMTV-MUC1DCT) and a third overexpressing human MUC1 lacking the tandem repeat extracellular domain (MMTV-MUC1DTR) (Schroeder et al., 2001) . The initial characterization of these transgenic mice focused on signal transduction initiated by MUC1 overexpression, resulting in the determination that MUC1 interacts with erbB receptors, and can modify the activation of Erk1/2 mitogen-activated protein kinases (MAPK) in an EGF-dependent manner. An expansion of our previous study included determining the effects of MUC1 overexpression over the lifetime of the mouse mammary gland. MMTV-MUC1 transgenic mice from two different founders (#9 and #15) were continuously bred for 12 months and then monitored as they aged. Cytoplasmic domain-deleted MUC1 transgenic mice (MMTV-MUC1DCT, #23) and wild-type controls were housed similarly. Tumors were observed in five out of eight MMTV-MUC1 mice and none were observed in the eight age-matched wild-type mice. As such, tumor incidence in the MMTV-MUC1 transgenic mice was 62% higher than in the wild-type mice (P ¼ 0.03, 95% CI ¼ 0.17-0.91). Statistical significance was determined using the Fisher's exact test. While primary mammary gland tumors were observed in both of the MMTV-MUC1 lines, no tumors were observed in either the MMTV-MUC1DCT transgenic line (three mice killed and analysed at 8 months and three mice at 20 months of age) or the wild-type control lines (analysed at 20 months). Pathological analysis of the tumors indicated a wide range of tumor subtypes in the MMTV-MUC1 transgenics, including papillary carcinoma (Figure 1a In addition, we observed tumors in the lungs of four of five MMTV-MUC1 transgenic mice with mammary gland tumors. The lung tumors express the MUC1 transgene as determined by immunohistochemical detection of the FLAG epitope present in the transgenic construct (Figure 1f ). While the FVB strain is prone to the development of primary lung tumors (at 14 months, 26% of FVB females develop spontaneous lung tumors; Mahler et al., 1996) , the percentage of pulmonary tumor formation in the presence of the MMTV-MUC1 transgene was substantially higher. These data indicate that mice transgenic for MMTV-MUC1 can develop primary mammary gland carcinomas as well as pulmonary carcinomas.
MUC1 overexpression results in sustained differentiation in multiparous animals All mice described above (whether tumor bearing or normal) were killed by 20 months of age and analysed for changes in the normal mammary gland architecture. The mammary glands of MMTV-MUC1DCT and wildtype females displayed the normal architecture expected from involutional regression (Figure 2c and d) . However, contralateral mammary glands from the MMTV-MUC1 animals were not regressed, but instead maintained a fully differentiated phenotype, although none of the animals were pregnant at the time of being killed or had been pregnant for at least 4 months prior to being killed (Figure 2a and b) . This ability to sustain a differentiated phenotype suggested that MUC1 overexpression may either inhibit apoptotic regression that normally follows the end of lactation or may promote hyperproliferation of epithelial cells.
To determine the rate at which the transformed phenotype was observable in the mammary gland of transgenic animals, we isolated mammary glands from 8-month-old lactating MMTV-MUC1 transgenic animals and wild-type littermates. In tumor-free MMTV-MUC1 animals, mammary glands were analysed for changes in normal architecture. In the MMTV-MUC1 transgenics but not in the age-matched wild-type females, we observed regions of the mammary gland that appeared histologically atypical from the normal lactating gland (Figure 3a , c). Hyperplastic epithelial cells were surrounded by adipose tissue and some secretory droplets were present despite the absence of full lactational development in those areas of the gland. In addition, we analysed a multiparous MMTV-MUC1 mammary gland that was not pregnant or lactating at the time of being killed. Histological analysis of this particular MMTV-MUC1 mammary gland revealed hyperplasia and abnormal architecture ( Figure 3b ) (M.D. Thomas Lidner, Mayo Clinic Scottsdale, personal communication).
MUC1 and b-catenin interact in MMTV-MUC1 tumors and hyperplasia and in MMTV-MUC1 lactating glands
b-catenin interacts with the cytoplasmic tail of MUC1 in a tumor-specific manner (Schroeder et al., 2003) . Through coimmunoprecipitation studies, we found that b-catenin interacts with the cytoplasmic tail of MUC1 in all MMTV-MUC1 tumors, but not in control wild-type mammary glands (Figure 4, upper panel) . This association between MUC1 and b-catenin was also detected in the lactating glands of 8-month-old MMTV-MUC1 mice and in two out of four of the age-matched lactating wildtype mice (Figure 5b, upper panel) . The interaction that occurs in the wild-type lactating gland could be attributed to the overexpression of Muc1 that occurs during lactation and the cellular changes associated with milk secretion. Note that while transgenic MUC1 was expressed (Figure 5a ), overall levels of both b-catenin and endogenous Muc1 were similar in both the transgenic and wild-type mammary glands (Figure 5b, middle and 
Increased pErk1 and pErk2 activation in the MMTV-MUC1 mammary glands
Previous studies with the MMTV-MUC1 transgenics have demonstrated that high levels of MUC1 in the lactating mouse mammary gland strongly induced EGFdependent activation of the extracellular signal-regulated protein kinases Erk1 (p44) and Erk2 (p42) (also known as MAPKs) (Schroeder et al., 2001 ). Erk1 and Erk2 are two downstream effectors of the EGFR and subsequent Ras signaling pathway, and are commonly activated in EGFR-induced transformation (Grant et al., 2002) . Thus, we were interested in determining the effects of MUC1 overexpression on Erk1 and Erk2 activation. We analysed seven approximately 8-month-old transgenic and six wild-type glands, and observed increased levels of dual phosphorylated Erk1 and Erk2 in five out of seven of the MMTV-MUC1 lactating glands as well as in the hyperplastic MMTV-MUC1 3.21.10 gland, while total Erk levels were similar to wild-type glands. A representative image is shown in Figure 5c .
MMTV-MUC1 transgenics exhibit delayed postlactational involution
In an effort to understand the mechanism of prolonged glandular differentiation in the older, multiparous MMTV-MUC1 transgenics, we analysed young uniparous females for differences in postlactational involution. Following lactation, the mammary gland normally involutes via apoptosis, resulting in a defined series of gene transcriptional events, adipose tissue deposition and the loss of differentiated epithelial alveoli (Strange et al., 2001) . MMTV-MUC1 transgenic and wild-type females were allowed to lactate for 6-10 days followed by pup removal to initiate involution. The animals were then killed at various time points and their mammary glands were analysed at days 2, 4, 6 and 8 of involution. We performed whole-mount analysis to assess any gross morphological differences between glands of MMTV-MUC1 transgenic and wild-type mice, and observed a delay in the postlactational involution of MMTV-MUC1 glands in comparison to the wild-type controls (Figure 6 ). At day 4 of involution, we noted the presence of lobuloalveolar structures in the mammary glands of both the MMTV-MUC1 transgenics (Figure 6a ) and the wild-type controls (Figure 6d ). By day 6 the collapse of lobulo-alveolar structures proceeded normally in the mammary glands of the wild-type females (Figure 6e ). In contrast, the mammary glands of MMTV-MUC1 transgenics were still filled with lobuloalveolar structures (Figure 6b ). At day 8 of involution, the wild-type glands had fully regressed (Figure 6f) , while large, MMTV-MUC1 and control wild-type mammary glands obtained at days 4, 6 and 8 were also sectioned and stained with hematoxylin and eosin to examine gland differentiation histologically. We observed no significant differences between MMTV-MUC1 and wild-type glands at days 4 and 6. However, at day 8 MMTV-MUC1 transgenics, showed large secretory ducts that were no longer present in the wild-type controls (data not shown). This delayed involution at day 8 in the transgenic gland correlates with high expression levels of the MUC1 transgene within the large secretory ducts (Figure 7 ). We performed immunohistochemical analysis to examine MUC1 expression in MMTV-MUC1 and control wild-type glands at days 4, 6 and 8. Wild-type animals were stained for endogenous Muc1 (Figure 7d-f) and MMTV-MUC1 animals were stained for the expression of the MUC1 transgene using an antibody specific to human MUC1 (Figure 7a-c) . Similar to wild-type Muc1, the MUC1 transgene was predominantly apically expressed within the alveolar lumens and secretory ducts. Figure 7f depicts the collapse of the lumenal spaces in the wildtype at day 8, while large lumenal spaces with appreciable amounts of MUC1 were present in the MMTV-MUC1 transgenics (Figure 7c ).
Increased whey acidic protein (WAP) expression
WAP is normally highly expressed during lactation and its expression is downregulated during the early phase of involution (Burdon et al., 1991; Marti et al., 1999) . We examined WAP expression by Western blot analysis in the transgenic and wild-type animals at days 2, 4, 6 and 8 of involution. As expected, WAP expression decreased in the wild-type mice from days 2 to 8. However, at day 6, a subset of MMTV-MUC1 glands (2/5) continued to express elevated levels of WAP when compared to wildtype mice (Figure 8) . We studied the expression levels and activation of a number of key apoptotic and antiapoptotic markers at days 2, 4, 6 and 8 of involution. We saw no observable differences in pStat3, pStat5, pAkt and caspase-3 (data not shown).
Decreased apoptosis in the MMTV-MUC1 mammary glands
Apoptotic cell death accounts for the disappearance of the epithelial compartment during mammary gland involution. In order to determine the mechanism by which MUC1 overexpression resulted in delayed mammary involution, we performed TUNEL assays to quantitate differences in apoptosis at day 2 of involution. We chose to analyse the mammary glands at that time Figure 7 MUC1 is highly expressed within the alveolar lumens and secretory ducts of MUC1 transgenic mice. Paraffin-embedded inguinal glands from MUC1 transgenic females (a-c) and wild-type controls (d-f) at day 4 of involution (a and d), day 6 of involution (b and e) and day 8 of involution (c and f). Immunohistochemical analysis of MUC1 transgenic mammary glands (a-c) using anti-MUC1 B27.29 (recognizes the PDTRPAP epitope in the tandem repeat of human MUC1). Wild-type glands (d-f) stained with CT2 (recognizes the last 17 amino acids of the cytoplasmic tail of both human and mouse Muc1). Wild-type glands stained with B27.29 were negative (data not shown). Images were captured at a magnification of Â 100 Figure 6 Mammary gland involution is delayed in the MUC1 transgenic mice. Representative images of whole mounts of involuting thoracic mammary glands from MMTV-MUC1 transgenic females (a-c) and wild-type controls (d-f) at day 4 of involution (a and d), day 6 of involution (b and e) and day 8 of involution (c and f). Arrows depict the large secretory ducts that are present in the MMTV-MUC1 glands at day 8 of involution. Images were captured at a magnification of Â 250 Figure 8 Increased WAP expression is observed in the mammary glands of MUC1 transgenics at day 6 of involution. Protein lysates (100 mg) from thoracic mammary glands of transgenic glands (MMTV-MUC1) and wild-type glands at day 6 of involution were examined by Western blot analysis for WAP expression. Increased WAP expression was observed in two out of five MUC1 transgenics, while it was completely absent in their wild-type counterparts at day 6 of involution point since that is when the majority of apoptosis takes place (Walker et al., 1989) . Figure 9a shows representative examples of TUNEL analysis on paraffin-embedded mammary glands of transgenic and wild-type mice. Mammary glands of MMTV-MUC1 transgenic mice displayed a reduced rate of apoptosis compared to the wild-type glands. We found that the percentage of apoptotic cells was 16.7 (76.1) for the wild-type glands and 4.8 (70.5) for MMTV-MUC1 transgenics, P ¼ 0.03 from the two-sample t-test (Figure 9b ).
Increased pErk2 activation in the MUC1 transgenic mammary glands
The MMTV-MUC1 transgenics display morphological inhibition of postlactational involution as detected by whole mount and histology (Figures 6 and 7) , biochemical inhibition as determined by continued expression of the differentiation protein WAP (Figure 8 ) and are functionally inhibited as shown by the failure of MMTV-MUC1 glands to undergo wild-type levels of apoptosis ( Figure 9 ). We next investigated if Erk1/2 was also aberrantly activated during involution. We examined mammary glands from both MUC1 transgenic and wild-type controls for their expression profile of Erk1 and Erk2 by Western blot analysis at days 2, 4, 6 and 8 of involution. While wild-type and transgenic glands displayed no difference in Erk1 and Erk2 activation at days 4 and 6 (data not shown), we detected increased Erk1/2 phosphorylation in the MMTV-MUC1 mammary glands when compared to their wild-type counterparts at day 2 (Figure 10a ). In addition, there was increased Erk2 activation in the MMTV-MUC1 transgenics at day 8 of involution, compared to the wild-type glands (Figure 10b ). This similarity between histological and biochemical alterations in the postlactational gland and glands contralateral to tumors may indicate that these alterations are requisite precursors to MUC1-induced transformation of the mammary gland.
Discussion
We have found that prolonged expression of MUC1 in the mouse mammary gland results in the stochastic development of unifocal tumors. Coincident with the development of frank neoplasia, prolonged expression of MUC1 inhibited postlactational involution by the inhibition of apoptosis. This is the first report to demonstrate that increased MUC1 expression is not merely a byproduct of transformation, but can itself promote transformation in a physiological context.
Frequently, these same mechanisms are observed as normal epithelium progresses to transformation, as is observed in the formation of hyperplastic alveolar nodules in precancerous mammary glands (Strange et al., 2001) . Mammary gland involution is a developmentally regulated process triggered upon cessation of lactation and consists of elimination of unneeded epithelial cells by apoptosis and subsequent tissue remodeling. It has been demonstrated that premalignant hyperplasias do not respond to apoptotic stimuli and fail to regress during postlactational involution (Strange et al., 2001) . It is likely that the sustained differentiation and the delay in involution in the MMTV-MUC1 mammary glands resulted in the persistence of a population of epithelial cells that are resistant to apoptosis and hormonal regulation. In turn, these cells could acquire additional mutations leading to transformation and ultimately the development of mammary tumors. Figure 10 Erk1 and Erk2 activation is increased at day 2 of involution in MMTV-MUC1 glands and Erk2 activation persists at day 8 in MMTV-MUC1 transgenic mammary glands. Protein lysates (100 mg) from thoracic mammary glands of transgenic glands (MMTV-MUC1) and wild-type glands were examined by Western blot analysis for Erk1 and Erk2 expression and activation at day 2 (a) and day 8 of involution (b). Erk1/2 were detected with p42/44 (Cell Signaling) and antibodies specific to dual phosphorylated Erk1/2 were used to detect active Erks (Sigma). (a) Increased Erk1/2 activation is observed in MMTV-MUC1 glands at day 2 of involution (a, upper panel) and no differences were observed in the levels of Erk1/2 (bottom panel). (b) pErk2 is still present in the MMTV-MUC1 transgenic mammary glands at day 8 of involution, while pErk2 is absent in the wild-type counterparts (upper panel). There is corresponding decrease in Erk2 levels in the wild-type compared to MUC1 transgenics (lower panel) Figure 9 MMTV-MUC1 glands exhibit decreased levels of apoptosis at day 2 of involution. (a) Representative images of MMTV-MUC1 and wild-type glands at day 2 of involution analysed by the TUNEL assay. Brown staining depicts apoptotic nuclei. Images were captured at a magnification of Â 400. (b) MMTV-MUC1 glands have a decreased percentage of apoptotic cells compared with wild-type glands at day 2 of involution In our study, we observed elevated Erk activation in lactating MMTV-MUC1 glands and in an MMTV-MUC1 hyperplastic nonlactating gland. Consistent with our findings, previous studies have linked MUC1 to Erk1/2 activation. We have previously demonstrated that MMTV-MUC1 transgenic mice undergoing lactation have the ability to activate Erk1/2 in response to EGF, whereas wild-type mammary glands do not (Schroeder et al., 2001) . In a separate study, Meerzaman et al. (2001) demonstrated the ability of CD8/MUC1 chimeric receptors to activate Erk2 phosphorylation in COS cells. Erk1 and Erk2 are serine/threonine protein kinases that belong to the highly conserved family of MAPKs that function in mediating cellular responses to a variety of extracellular signals (Kolch, 2000) . Overexpression of Erk1 and Erk2 has been detected in breast cancer cells with a five-to 10-fold increase in activity over benign conditions. The overexpression of Erk1 and Erk2 was detected in epithelial cells of primary breast cancer as well as at distant metastases (Sivaraman et al., 1997) . A recent study found that Erk1 and Erk2 are not only overexpressed but also hyperactivated in human breast tumors compared with normal tissue. Interestingly, Erk2 expression levels were higher than Erk1 in most tumor samples (Mueller et al., 2000) . Not much is known about the independent functions of Erk2 as opposed to Erk1; however, it has been reported that Erk2 plays a critical role in mediating EGF-stimulated proliferation in MCF-7 breast cancer cells (Flury et al., 1997) . The specific downstream effects of Erk1 and Erk2 activation in the mammary epithelial cells are still not defined. However, a recent report indicates that inhibition of Erk1 and Erk2 activation results in increased apoptosis after BRCA1 expression in MCF-7 breast cancer cells (Yan et al., 2002) . This suggests that the increases in Erk1 and Erk2 activation associated with MUC1 overexpression could provide a mechanism for the failure to eliminate cells by apoptosis, resulting in premalignant hyperplasia that contributes to mammary tumors.
The current question pertaining to understanding the role of MUC1 in cancer is delineating which domain of MUC1 is necessary to drive tumorigenesis. Much research has focused on studying the cytoplasmic domain of MUC1, which contains seven conserved tyrosine residues and a number of consensus binding motifs. MUC1 cytoplasmic tail interacts with a variety of proteins involved in neoplasia and cell adhesion such as EGFR, erbB2, erbB3, erbB4, PKCd, Grb2, bcatenin, GSK3b and p120 ctn (Pandey et al., 1995; Yamamoto et al., 1997; Li and Kufe, 2001; Li et al., 2001a, b; Schroeder et al., 2001 Schroeder et al., , 2003 Ren et al., 2002) . c-Src and erbB receptor tyrosine kinases and the serine/ threonine kinase PKCd are among the kinases that are known to phosphorylate the cytoplasmic domain of MUC1. The phosphorylation of the cytoplasmic tail of MUC1 is thought to regulate its association with two antagonistic proteins, b-catenin and GSK3b. MUC1, through its various cytoplasmic tail interactions, may act as a scaffolding protein to enhance growth-promoting and oncogenic signals. It will be interesting to determine whether the lack of the cytoplasmic tail of MUC1 will alter the delayed involution phenotype observed in the MMTV-MUC1 mice.
Previously, our lab has demonstrated that tumorspecific MUC1/b-catenin complexes are detected in primary breast tumors and metastatic lesions (Schroeder et al., 2003) . We speculated that these complexes may promote metastatic invasion by directing b-catenin to the leading edge of the cell and facilitating its interaction with fascin. Recently published studies described the association between the cytoplasmic tail of MUC1 and b-catenin in the nucleus of human pancreatic cancer cell lines and in the nucleus of multiple myeloma cells (Li et al., 2003a; Wen et al., 2003) . In a recently published report, stable expression of human MUC1 in rat 3Y1 fibroblasts resulted in anchorage-independent growth of the cells and tumor formation upon injection into nude mice (Li et al., 2003b) . Analysis of the tumor sections depicted the presence of the cytoplasmic tail of MUC1 in the nucleus in a complex with b-catenin (Li et al., 2003b) . In fact, the cytoplasmic tail has been shown to activate transcription of cyclin D1, a b-catenin target gene. Mutation of Y46, a critical residue within the cytoplasmic tail of MUC1 that regulates its association with b-catenin, was found to attenuate the function of MUC1 as a transcriptional activator of Wnt target genes and also abrogate its transforming capability (Huang et al., 2003) . In the current study, we have shown that the association between b-catenin and MUC1 exists in the MMTV-MUC1 induced tumors but not in the normal mammary gland. We also observe this association in the hyperplastic glands of the MMTV-MUC1 transgenic mice. This suggests that MUC1/b-catenin complex formation may be an early event in mammary transformation.
MUC1 has long been recognized as a tumorassociated antigen. More than 90% of human breast cancers overexpress MUC1. MUC1 overexpression in cancer is thought to influence adhesion, invasion and immune surveillance. Recent work has highlighted a role for the cytoplasmic domain of MUC1 in cell signaling that contributes to malignant transformation of epithelial cells. Similar to the human breast tumors, mouse models of breast cancer such as the MMTV-PyV MT and MMTV-Wnt-1 transgenic mice exhibit overexpression of Muc1. The lack of Muc1 expression causes a significant delay in tumor onset in the MMTV-Wnt-1 mice, suggesting that Muc1 is involved in the initiation stages of cancer in that b-catenin-dependent model. Recent in vitro studies demonstrate the ability of MUC1 to transform cells. We now show that the overexpression of MUC1 is directly involved in the in vivo transformation of the mammary gland.
Materials and methods
Transgenic animals
Transgenic mice that express the 42 tandem repeat human MUC1 cDNA (referred to as MMTV-MUC1) or human MUC1 lacking the cytoplasmic tail (referred to as MMTV-MUC1DCT) have been described previously (Schroeder et al., 2001) . Transgenic mice were maintained on an inbred FVB background and wild-type littermates were used as controls. Two separate MMTV-MUC1 lines (MMTV-MUC1#9 and #15), line #23 of MMTV-MUC1DCT and wild-type littermates were bred continuously for 12 months and then monitored for tumor development. Human MUC1 and mouse Muc1 are distinguished as such.
Induction of involution
Uniparous wild-type or transgenic MMTV-MUC1 female mice were allowed to lactate for 6-10 days to allow for full development of lactation, and the day the pups were removed was counted as day 0 of involution. Only mice having litters of 45 pups were included in the study. The animals were killed at 2, 4, 6 or 8 days after pup removal and the mammary glands were harvested.
Whole mounts
Whole mounts of thoracic and inguinal glands were prepared by spreading the glands on a glass slide and fixing in a 1 : 3 solution of glacial acetic acid and absolute ethanol for 1 h. Following fixation, the glands were washed with 95% ethanol for 15 min, followed by a wash with absolute ethanol for 15 min. The glands were defatted overnight through four changes of acetone. The glands were then rehydrated and stained overnight in 0.2% carmine and 0.5% aluminum potassium sulfate. Destaining was performed by washing for 15 min each in 70% ethanol then 95% ethanol followed by absolute ethanol and then 95% ethanol and finally 70% ethanol. The slides were then stored in glycerol.
Protein analysis
Thoracic glands were prepared for Western blot analysis as described previously in Schroeder et al. (2001) . Protein concentrations were determined by BCA (Pierce). Protein lysates (100 mg) were separated by SDS-PAGE and transferred to polyvinylidene difluoride membrane (Immobilon). Immunoprecipitations were performed with 1 mg of protein lysate using recombinant protein G-agarose conjugate (Invitrogen). Antibodies for immunoblotting were obtained from the following sources: CT2, a hamster monoclonal antibody developed in house to the cytoplasmic tail of MUC1. CT2 recognizes the cytoplasmic tail of both human MUC1 and mouse Muc1. HMFG-2 and B27.29 are mouse monoclonal antibodies that recognize the tandem repeat of human MUC1. HMFG-2 was the kind gift from Dr Joyce Taylor-Papadimitriou (ICRF, London, UK). B27.29 was kindly provided by Biomira (Edmonton, Alberta, Canada). b-catenin H-102 (10 mg) was used for immunoprecipitation and b-catenin C-18 was used for immunoblotting, both from Santa Cruz; Erk1/2 (Cell Signaling, #9102), dpErk1/2 (Sigma Chemical Company, M8159) and WAP (Santa Cruz Biotechnology, M16) were also used. For immunoblotting, the antibodies were used at the following dilutions: CT2 (1 : 500), HMFG-2 (1 : 20), B27.29 (1 : 1000), b-catenin (1 : 1000), Erk1/2 (1 : 1000), dpErk1/2 (1 : 10 000) and WAP (1 : 500). HRP-conjugated secondary antibodies were from Pierce and Jackson Laboratories and used at 1 : 25 000.
Immunohistochemistry
Inguinal mammary glands were fixed in methacarn (methanol : chloroform : acetic acid, 6 : 3 : 1) or formalin and processed as described previously (Schroeder et al., 2001) . Dilutions for antibodies are as follows. anti-MUC1, B27.29 (1 : 500), antiMuc1 or anti-MUC1, CT2 (1 : 400). Lung metastases were stained with an antibody to the FLAG epitope tag, M5 (1 : 100, Sigma).
TUNEL
The Apoptag Plus Peroxidase In Situ Apoptosis Detection kit (Serologicals Corporation) was used to identify apoptotic nuclei within the mammary glands. Formalin-fixed inguinal mammary glands (at day 2 of involution) from three separate MMTV-MUC1 and three wild-type controls were analysed. The protocol outlined by the manufacturer was modified as described by Garrity et al. (2003) . We stained duplicate sections and a minimum of 1000 cells was counted per section covering 20 randomly chosen fields ( Â 400). The number of apoptotic cells was calculated as a percentage of total cell count. Statistical significance was determined using the twosample t-test.
